PDCD1 and neoplasm: We thus hypothesized that cDHPs could improve PD-1/PD-L1 antibody efficacy by increasing effector T cell and NK cell infiltration abundance through inhibition of IL-35 expression and enhancing anti-tumor immunity (Supplementary material 2).